TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
LYEL

Lyell Immunopharma Inc

Healthcare · Biotechnology

9.70$ -1.1% vs. previous close Closing price · As of: Sep 28, 2026

Statements

Balance Sheet

Lyell Immunopharma Inc (LYEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 311 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet LYEL
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
795 750 694 654 619 491 430 385 408 340 351 311
587 555 534 500 450 380 309 282 328 261 267 214
286 146 126 133 100 106 120 99 124 60 91 73
575 546 526 491 441 371 301 277 320 247 254 204
97 95 91 88 89 108 93 87 79 92 77 77
35 35 32 31 34 54 41 37 32 49 37 40
6.1 6.3 6.7 6.9 7.1 8.0 8.2 8.5 8.8 9.1 9.4 –
4.4 4.8 4.9 4.2 3.6 5.4 3.7 3.4 2.6 2.9 5.5 3.9
698 655 603 567 531 383 337 299 329 248 274 234
-949 -1,002 -1,063 -1,109 -1,153 -1,345 -1,397 -1,440 -1,479 -1,620 -1,644 -1,688
13 13 13 13 13 13 15 15 18 17 22 23

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?